Hospital Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024
- Transparency Market Research
- Medical Equipments
Hospital Cancer Diagnostics Market: Overview
Cancer is an acute disease caused by genetic malfunctions. Early diagnosis of cancer is very critical for providing accurate and effective treatment. A patient is subjected to variety of tests and exams in hospital as well as in the laboratories. Pap test was the first screening test used for detection of cancer which was promoted in the 1960s by the American Cancer Society. Significance of this test was that it helped in early diagnosis and treatment of cervical cancer leading to decline in death rate of cervical cancer patients by about 70%.
In recent years, cancer diagnostics have evolved rapidly with introduction of new technologies and applications. Today several types of cancers are diagnosed using wide array of methods. The global market for hospital cancer diagnostics is expanding at exponential rate due to rising prevalence of cancer across the globe. Additionally, the advancement in understanding and treating cancer coupled with high awareness about the disease has heightened the demand for cancer diagnosis worldwide.
Hospital Cancer Diagnostics Market: Segmentation
The global hospital diagnostics market is segmented on the basis of type of cancer, such as breast cancer, bladder cancer, lung cancer, leukemia, lymphoma, oral cancer, skin cancer, uterine cancer, ovarian cancer, colon and rectal cancer, prostate cancer, stomach cancer, and other cancers.
The most common methods utilized for cancer diagnosis in hospital include laboratory tests (blood & urine tests), biopsy, endoscopy, diagnostic imaging, genetic tests, nuclear medicine scans (bone scans, etc.), and hematology tests. Diagnostic imaging for cancer diagnosis used several techniques like x-rays, CT (computerized tomography) and CAT (computerized axial tomography) scans, magnetic resonance imaging (MRI), ultrasound, mammography and positron emission tomography (PET) scanning.
Next generation cancer diagnostics include lab-on-a-chip, microarrays, multiplexed assays, next generation sequencing (NGS), pyro-sequencing, RT-PCR, Spectral Karyotyping (SKY), and cellular capture and identification. These technological advancements are creating favorable conditions for market growth.
Hospital Cancer Diagnostics Market: Regional Overview
Geographically, the global market for hospital cancer diagnostics is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. The World Health Organization has highlighted the disparity in policies on early cancer detection among several countries in the world. In developed countries such as the U.S., Canada, and some major countries in European Union, cancer screening programs for detecting cancer are common and more encouraged in comparison to least developed countries. Therefore, the present market for hospital diagnostic testing is dominated in North America and Europe while the future market lied in the potential markets of Asia-Pacific region.
According to WHO report, more than 60% of world’s total new annual cases occur in Africa, Asia and Central and South America. Lack of early diagnosis caused patients to die and these regions account for approximately 70% of the global cancer deaths. Such high prevalence of cancer disease in these regions will compel governments in these nations to implement cancer screening programs.
Hospital Cancer Diagnostics Market: Key Players
Some of the major companies which provide technology platforms and diagnostic technology for cancer diagnosis include Abbott, AdnaGen AG, Applied Genetic Technologies Corporation, Beckman Coulter/Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Dako (a Agilent Technologies company), Cepheid, Inc., diaDexus, Inc., Myriad Genetics, Inc., QIAGEN N.V., Hologic Corporation, Ortho Clinical Diagnostics (a Johnson & Johnson company), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Corporation, Sequenom, Inc. and GE Healthcare.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
- Middle East and Africa (GCC, Southern Africa, North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Medical Equipments
Medical DevicesNebulizers-Medical Devices Pipeline Product Landscape, 2021